Symkevi/Kalydeco cleared for use in young CF patients
The combination is the first available to treat the underlying cause of CF in this patient group.
Read More
Tag: Symkevi
Vertex signs ‘landmark’ deal with NHS for CF therapy
CF patients in England will be among the first in Europe to benefit from access to Kaftrio, if the medicine is approved by the EC
Read More
Vertex to submit Orkambi, Symkevi to SMC
Vertex has revealed that it will be submitting its cystic fibrosis medicines Orkambi and Symkevi to the Scottish Medicines Consortium for appraisal, following “constructive discussions” with the Scottish government.
Read More
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
